慢性淋巴细胞白血病（CLL）是成人患者中最常见的白血病类型之一。在过去的几十年里，随着基于抗体的疗法和新型靶向药物的引入，CLL 治疗的情况发生了变化，从而改善了治疗结果。本文介绍了单克隆抗体、双特异性抗体和抗体药物偶联物在治疗复发性和慢性淋巴细胞白血病中的应用。难治性慢性淋巴细胞白血病。讨论了基于抗体的疗法（无论是单一疗法还是与其他药物联合疗法）的作用机制、临床应用和安全性。使用 PubMed、Web of Science 和 Google Scholar 对以英文发表的文章进行文献检索。通过审查所选文章中的参考文献，获得了其他相关出版物。基于抗体的治疗策略极大地改变了 CLL 的治疗，因为它们引入了增强针对肿瘤细胞的免疫反应的概念。虽然免疫疗法通常有效，但由于抗原丢失、突变或下调，可能会出现一些治疗失败，这仍然是治愈的主要障碍。新型抗体疗法的开发，包括与靶向药物和双特异性抗体的组合，可能有助于降低毒性并提高疗效。

Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adult patients. The landscape of CLL therapy has changed in the last decades with the introduction of antibody-based therapies and novel targeted agents resulting in improved outcomes.This article describes the use of monoclonal antibodies, bispecific antibodies and antibody-drug conjugates in the treatment of relapsed and refractory CLL. The mechanism of action and clinical applications and safety of antibody-based therapies, both as monotherapy and in combination with other drugs, are discussed. A literature search was performed using PubMed, Web of Science, and Google Scholar for articles published in English. Additional relevant publications were obtained by reviewing the references from the chosen articles.Antibody-based therapeutic strategies have drastically changed the treatment of CLL, as they have introduced the concept of boosting immune responses against tumor cells. While immunotherapy is generally effective, some treatment failure can occur due to antigen loss, mutation, or down-regulation, and this remains the main obstacle to cure. The development of novel antibody therapies, including their combinations with targeted drugs and bispecific antibodies, might help to reduce toxicity and improve efficacy.